Answers are grounded in this paper and cite their sources.
In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).
No takes yet. Share an insight, caveat, or question.
Adams et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: